Similarly, dopamine D2 receptor antagonists have been shown to ameliorate mutant tau-induced functional defects and reduce aggregation in a frontotemporal dementia with parkinsonism-17 (FTDP-17) tauopathy model [10]. This evidence concerns the gene MAPT and tauopathy.